| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 10, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 163,730 | $630.59 | $103,246,373.25 | - | +20.2% | +26.9% | |
| Jan 10, 2024 | SUPN Supernus Pharmaceuticals, Inc. | Martin Tami Tillotson54 | Sr. V.p., Regulatory Affairs | Sell | 8,000 | $27.91 | $223,280.00 | -8.5% | +12.8% | +33.2% | |
| Jan 10, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | Luo Mary Z.71 | COO,Chief Scientist &Chairman | Sell | 131,386 | $54.59 | $7,171,767.74 | -2.9% | -25.4% | -33.7% | |
| Jan 10, 2024 | ORGO Organogenesis Holdings Inc. | Erani Albert79 | 10% Owner | Sell | 215,893 | $4.36 | $940,859.77 | -0.2% | -28.4% | -26.2% | |
| Jan 10, 2024 | ORGO Organogenesis Holdings Inc. | Erani Albert79 | 10% Owner | Sell | 215,893 | $4.36 | $940,859.77 | -0.2% | -28.4% | -26.2% | |
| Jan 9, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 34,538 | $631.81 | $21,821,412.51 | - | +24.3% | +25.9% | |
| Jan 9, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Yeramian Patrick D84 | Chief Medical Officer | Sell | 2,812 | $16.33 | $45,914.62 | -1.3% | -83.6% | -77.0% | |
| Jan 9, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Klee Justin B.60 | Co-chief Executive Officer | Sell | 5,841 | $16.33 | $95,372.43 | -0.2% | -83.6% | -77.0% | |
| Jan 9, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Frates James M83 | Chief Financial Officer | Sell | 2,716 | $16.33 | $44,347.12 | -2.4% | -83.6% | -77.0% | |
| Jan 9, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Cohen Joshua B60 | Co-chief Executive Officer | Sell | 5,841 | $16.33 | $95,372.43 | -0.2% | -83.6% | -77.0% | |
| Jan 9, 2024 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 167,858 | $133.02 | $22,328,417.31 | -14.4% | +4.3% | +3.7% | |
| Jan 9, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | Luo Mary Z.71 | COO,Chief Scientist &Chairman | Sell | 219,800 | $58.23 | $12,798,708.11 | -1.6% | -27.8% | -35.5% | |
| Jan 5, 2024 | ETST Earth Science Tech, Inc. | Sanchez Yovan Arturo | Director | Buy | 50,000 | $0.05 | $2,500.00 | +12.5% | - | - | |
| Jan 4, 2024 | VTRS Viatris Inc | Cuneo Andrew49 | See Remarks | Sell | 4,000 | $11.50 | $46,000.00 | -8.5% | +4.1% | +6.3% | |
| Jan 4, 2024 | DVAX Dynavax Technologies Corp | Janssen Robert71 | SVP And CMO | Sell | 1,500 | $15.00 | $22,500.00 | -2.9% | -18.6% | -13.6% | |
| Jan 4, 2024 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $227.97 | $1,367,798.18 | -5.0% | +0.5% | +54.9% | |
| Jan 4, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 14,388 | $630.28 | $9,068,445.34 | - | +26.3% | +27.3% | |
| Jan 3, 2024 | KNSA Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | Chief Financial Officer | Sell | 12,000 | $20.00 | $240,000.00 | -43.4% | -6.3% | -0.2% | |
| Jan 2, 2024 | DVAX Dynavax Technologies Corp | Novack David F73 | President &COO | Sell | 9,000 | $14.45 | $130,050.00 | -73.8% | -12.5% | -10.3% | |
| Jan 2, 2024 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 75,000 | $131.47 | $9,860,194.47 | -22.4% | +7.3% | +4.7% | |
| Jan 2, 2024 | KNSA Kiniksa Pharmaceuticals International, Plc | Megna Michael R | Chief Accounting Officer | Sell | 16,670 | $19.17 | $319,563.90 | -49.5% | +6.3% | +7.6% | |
| Jan 2, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $61.37 | $30,682.93 | -0.3% | -30.3% | -41.6% | |
| Jan 2, 2024 | NBIX Neurocrine Biosciences Inc | Rastetter William H48 | Director | Sell | 11,044 | $131.47 | $1,451,927.07 | -17.6% | +7.3% | +4.7% | |
| Jan 2, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 13,744 | $8.80 | $120,947.20 | -8.2% | +62.4% | +161.4% | |
| Dec 29, 2023 | CGC Canopy Growth Corp | Lazzarato David Angelo75 | Director | Sell | 3,713 | $6.68 | $24,802.84 | -17.9% | +68.9% | -45.6% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.